Bert Heyrman

Dr. Bert Heyrman

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
BHBert Heyrman
Bert Heyrman
SMStef Meers
Stef Meers
AVAnn Van De Velde
Ann Van De Velde
SASébastien Anguille
Sébastien Anguille
Despite the motivation of oncology patients to take part in clinical trials, only a minority of them are enrolled in clinical trials. Implementation of new practical procedures can become a barrier that withholds patients from participating in clinical trials. Treating physicians are crucial in augmenting trial accrual. The drivers that promote physicians to allocate patients for clinical trials need further assessment. We conducted two separate cross-sectional surveys, addressing patients with a haematological disease in one survey and haematologists in another survey. The patient survey was filled out by 420 patients. Significant relationships between the willingness to participate in a trial and trial knowledge (p < 0.001) and between doctor–patient relationship and participation willingness (p = 0.007) were noted. Patients above 60 years were less willing to use an electronic consent procedure vs. patients younger than 60 (p < 0.001). The physician questionnaire was completed by 42 participants of whom most (83%) were active in and (94%) motivated for clinical trials. Apart from the patient benefit and scientific interest, prestige was an equal motivator closely followed by financial remunerations. First goal was not to harm the patient. Our study confirms the high willingness of patients for trial participation and the need to rethink the structure of trial organisation. The e-consent procedure is not the method preferred by most patients above 60 years old.

22 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BHBert Heyrman
Bert Heyrman
SMStef Meers
Stef Meers
ABAnn De Becker
Ann De Becker
KWKristien Wouters
Kristien Wouters
AHAchiel Van Hoof
Achiel Van Hoof
SASébastien Anguille
Sébastien Anguille
Patients with myelodysplastic syndromes suffer from an impaired quality of life that is only partially explained by physical symptoms. In an observational study, we aimed to investigate the impact of current MDS treatments and the influence of disease perception on quality of life. Serial measurement of health-related quality of life was performed by ‘the QUALMS’, a validated MDS-specific patient reported outcome tool. Disease perception was evaluated by means of the Brief Illness Perception Questionnaire (B-IPQ). We prospectively collected data on 75 patients that started on a new treatment and could not demonstrate a significant change in QUALMS score or B-IPQ score during treatment. Six out of eight items evaluated in the B-IPQ correlated significantly with QUALMS score. In this small sample, no significant difference in QUALMS score was found between lower vs. higher risk MDS patients or other studied variables, e.g., targeted hemoglobin showed no correlation with QUALMS score. In daily practice attention must be paid to initial formation of disease perception as it correlates independently with health-related quality of life and does not change during treatment (clinicaltrials.gov identifier: NCT04053933).

3 May 2024 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
DDDaan Dierickx
Daan Dierickx
TCThierry Connerotte
Thierry Connerotte
JDJulie Dallemagne
Julie Dallemagne
ABAnn De Becker
Ann De Becker
IMIne Moors
Ine Moors
VDVanessa Delrieu
Vanessa Delrieu

4 October 2024 in eJHaem
Verified
Journal Article
Open access
BHBert Heyrman
Bert Heyrman
SMStef Meers
Stef Meers
SSSélim Sid
Sélim Sid
NPNatalie Put
Natalie Put
KTKoen Theunissen
Koen Theunissen
SASébastien Anguille
Sébastien Anguille

27 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BHBert Heyrman
Bert Heyrman
The opinion I put forward in this paper is that attention must be paid to health-related quality of life as a study endpoint in lower-risk MDS patients. At the moment therapeutic options are limited in this population. New treatments are predominantly available in clinical studies. In announcing trial publications and during manuscript introductions, quality of life is widely valued as a treatment goal. However, data on health-related quality of life during phase III studies are not published in the original publications, thereby undermining the importance of quality of life as a study endpoint. What seems to be forgotten is that quality of life comprises more than a study endpoint. It is the highest good of lower-risk MDS patients and should also be acknowledged as a safety aspect. Current phase II trials with new medications do not collect data on health-related quality of life, a practice that I consider unethical. In this opinion I demonstrate the current attitude towards health-related quality of life in lower risk MDS patients among leading journals and trial sponsors with several recent examples. I also argue that health-related quality of life should be the main treatment goal in this population. In the event that we shift our focus towards health-related quality of life as the main treatment goal, new treatments could come to a field where gains in overall survival have been marginal over the years.

21 May 2025
Verified
Thesis
Closed access
BHBert Heyrman
Bert Heyrman
Myelodysplastic syndromes or neoplasms (MDS) are a group of complex hematological malignancies that result in malfunctioning of the bone marrow. They all carry a risk of progression towards acute myeloid leukemia. Allogeneic stem cell transplantation is the only curative treatment for this group of malignancies. With a median age of 70 at diagnosis, most patients are considered not to be eligible for transplantation. Since most treatments have no curative potential and minimal impact on overall survival, quality of life is uniformly recognized as a treatment goal. Although recognized as a therapeutic objective, data on quality of life in patients with MDS outside clinical trials where lacking at the start of this project. We set up a national study to evaluate the impact of current available therapies on quality of life in MDS patients. This observational trial demonstrated a significant correlation between the patients’ perception of MDS and health related quality of life in MDS patients. However, the drop in inclusion due to the COVID pandemic did not allow a firm conclusion on the therapeutic impact on quality of life. Low inclusion rates into clinical trials are the most frequent reason for trial failures. We explored the hematology patients’ drivers to participate in clinical trials during a collaborative effort in the province of Antwerp and hematologists’ drivers for trial inclusion in a national survey. We concluded that patients express a high willingness to trial participation but a knowledge-gap concerning general understanding of clinical trial concepts was present. We therefore created an information brochure in collaboration with the Patient Committee of the Belgian Hematology Society. The brochure is available online and as a hard-copy. Physicians have an important role in trial inclusions. The physicians’ interest in the study objective is an important motivator for trial inclusion. In an opinion letter we discussed the current attitude towards quality of life as a study endpoint. To our opinion quality of life is undervalued as a study endpoint during different phases of clinical trials. The importance of health related quality of life (HRQoL) was demonstrated during another national collaboration during which we collected real-life data on the use of luspatercept, a relatively new molecule in the field of MDS. We demonstrated the importance of quality of life in MDS patients, an assumption we made incorrectly at the start of this project. We hereby missed our primary objective that was to explore treatment impact on quality of life in MDS. We hope this work can be an incentive for future projects.